biosimilars

FTC Raises Concerns About Efforts to Blunt Rx Competition

Posted on 04/10/2014 by | AARP Blog Author | Comments

Public Policy InstituteBiologic drugs are often used to treat health conditions that affect older populations — diseases such as cancer, multiple sclerosis and rheumatoid arthritis. Derived from living organisms, biologics have an estimated average cost of $35,000 a year, which is far more than that of traditional, chemically derived drugs. Congress recently granted the Food and Drug Administration (FDA) authority to approve less expensive generic versions of biologic drugs, known as biosimilars or follow-on biologics. But while the FDA continues to work …

State Laws Could Hamper Savings from Biosimilar Drugs

Posted on 05/30/2013 by | AARP Blog Author | Comments

Public Policy Institute  Many consumers have benefited from the recent increase in brand-name drugs that are going off patent, allowing less expensive generic drugs to enter the market.  The same may happen with a new type of drugs known as biologics — but only if the generic versions of these drugs are allowed to reach consumers. Biologic drugs are medicines derived from living organisms that are often used to treat health conditions that commonly affect older populations, such as cancer, multiple sclerosis …